Allogene Therapeutics, Inc.
For the period ended Aug 12, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 12, 2026 · Filed Aug 12, 2026
Use the contents to explore the available documents and sections.
ALLO$1.04-4.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
STATEMENTS OF OPERATIONS
| Three Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue - related party | $4,640 | $— |
| Operating expenses: | ||
| Research and development | $30,721 | $40,156 |
| General and administrative | 20,839 | 14,281 |
| Impairment of long-lived assets | — | 2,382 |
| Total operating expenses | 51,560 | 56,819 |
| Loss from operations | (46,920) | (56,819) |
| Other income (expenses), net: | ||
| Interest and other income, net | 4,647 | 6,187 |
| Interest expense | (343) | (268) |
| Other income (expenses), net | (61) | (43) |
| Total other income (expenses), net | 4,243 | 5,876 |
| Net loss | $(42,677) | $(50,943) |
| Net loss per share, basic and diluted | $(0.13) | $(0.23) |
| Weighted-average number of shares used in computing net loss per share, basic and diluted | 328,930,269 | 218,929,548 |
SELECTED BALANCE SHEET DATA
| As of June 30, 2026 | As of December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and investments | $423,590 | $258,253 |
| Total assets | 550,091 | 415,905 |
| Total liabilities | 113,916 | 123,363 |
| Total stockholders’ equity | 436,175 | 292,542 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.